283 related articles for article (PubMed ID: 16176495)
21. A cost-effectiveness analysis of combination antiplatelet therapy for high-risk acute coronary syndromes: clopidogrel plus aspirin versus aspirin alone.
Schleinitz MD; Heidenreich PA
Ann Intern Med; 2005 Feb; 142(4):251-9. PubMed ID: 15710958
[TBL] [Abstract][Full Text] [Related]
22. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
23. [An acetylsalicylic acid-dypiridamole combination (Asasantine) in the prevention of the recurrence of cerebrovascular accidents (a cost-effectiveness analysis)].
Kurz X; Annemans L; Dresse A
Rev Med Liege; 1998 May; 53(5):265-9. PubMed ID: 9689880
[TBL] [Abstract][Full Text] [Related]
24. Clopidogrel versus aspirin in patients with atherothrombosis: a CAPRIE-based cost-effectiveness model for Greece.
Kourlaba G; Fragoulakis V; Maniadakis N
Appl Health Econ Health Policy; 2012 Sep; 10(5):331-42. PubMed ID: 22853743
[TBL] [Abstract][Full Text] [Related]
25. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease.
Gaspoz JM; Coxson PG; Goldman PA; Williams LW; Kuntz KM; Hunink MG; Goldman L
N Engl J Med; 2002 Jun; 346(23):1800-6. PubMed ID: 12050341
[TBL] [Abstract][Full Text] [Related]
26. One-year follow-up healthcare costs of patients hospitalized for transient ischemic attack or ischemic stroke and discharged with aspirin plus extended-release dipyridamole or clopidogrel.
Burton TM; Lacey M; Liu F; Yu Y; Monsalvo ML; Lang K; Sander S
J Med Econ; 2012; 15(6):1217-25. PubMed ID: 22857539
[TBL] [Abstract][Full Text] [Related]
27. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
28. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
Wu B; Kun L; Liu X; He B
Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Malloy RJ; Kanaan AO; Silva MA; Donovan JL
Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
[TBL] [Abstract][Full Text] [Related]
30. Acetylsalicylic acid + extended-release dipyridamole combination therapy for secondary stroke prevention.
Chaturvedi S
Clin Ther; 2008 Jul; 30(7):1196-205. PubMed ID: 18691981
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of clopidogrel in STEMI patients in the Netherlands: a model based on the CLARITY trial.
Thurston SJ; Heeg B; de Charro F; van Hout B
Curr Med Res Opin; 2010 Mar; 26(3):641-51. PubMed ID: 20070142
[TBL] [Abstract][Full Text] [Related]
32. Impact of persistence with antiplatelet therapy on recurrent ischemic stroke and predictors of nonpersistence among ischemic stroke survivors.
Burke JP; Sander S; Shah H; Zarotsky V; Henk H
Curr Med Res Opin; 2010 May; 26(5):1023-30. PubMed ID: 20199138
[TBL] [Abstract][Full Text] [Related]
33. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke.
Sacco RL; Diener HC; Yusuf S; Cotton D; Ounpuu S; Lawton WA; Palesch Y; Martin RH; Albers GW; Bath P; Bornstein N; Chan BP; Chen ST; Cunha L; Dahlöf B; De Keyser J; Donnan GA; Estol C; Gorelick P; Gu V; Hermansson K; Hilbrich L; Kaste M; Lu C; Machnig T; Pais P; Roberts R; Skvortsova V; Teal P; Toni D; Vandermaelen C; Voigt T; Weber M; Yoon BW;
N Engl J Med; 2008 Sep; 359(12):1238-51. PubMed ID: 18753638
[TBL] [Abstract][Full Text] [Related]
34. Modelling the long term cost effectiveness of clopidogrel for the secondary prevention of occlusive vascular events in the UK.
Karnon J; Brennan A; Pandor A; Fowkes G; Lee A; Gray D; Coshall C; Nicholls C; Akehurst R
Curr Med Res Opin; 2005 Jan; 21(1):101-12. PubMed ID: 15881481
[TBL] [Abstract][Full Text] [Related]
35. The long-term cost-effectiveness of clopidogrel plus aspirin in patients undergoing percutaneous coronary intervention in Sweden.
Lindgren P; Stenestrand U; Malmberg K; Jönsson B
Clin Ther; 2005 Jan; 27(1):100-10. PubMed ID: 15763611
[TBL] [Abstract][Full Text] [Related]
36. Replacing aspirin and warfarin for secondary stroke prevention: is it worth the costs?
Hankey GJ
Curr Opin Neurol; 2010 Feb; 23(1):65-72. PubMed ID: 19949330
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness of clopidogrel in myocardial infarction with ST-segment elevation: a European model based on the CLARITY and COMMIT trials.
Berg J; Lindgren P; Spiesser J; Parry D; Jönsson B
Clin Ther; 2007 Jun; 29(6):1184-202. PubMed ID: 17692733
[TBL] [Abstract][Full Text] [Related]
38. Long-term cost-effectiveness of clopidogrel given for up to one year in patients with acute coronary syndromes without ST-segment elevation.
Weintraub WS; Mahoney EM; Lamy A; Culler S; Yuan Y; Caro J; Gabriel S; Yusuf S;
J Am Coll Cardiol; 2005 Mar; 45(6):838-45. PubMed ID: 15766816
[TBL] [Abstract][Full Text] [Related]
39. [Antithrombotic therapy after cerebral ischemia].
Schellinger PD; Orberk E; Hacke W
Fortschr Neurol Psychiatr; 1997 Sep; 65(9):425-34. PubMed ID: 9417427
[TBL] [Abstract][Full Text] [Related]
40. Aggrenox((R)) versus other pharmacotherapy in preventing recurrent stroke.
Redman AR; Ryan GJ
Expert Opin Pharmacother; 2004 Jan; 5(1):117-23. PubMed ID: 14680441
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
